

2022 #21

June 10, 2022

INSIDE:

RESEARCH IN BRIEF2
 PEOPLE3
 IN MEMORIAM4
 MEMBER NEWS.....5
June Blood Bulletin
 Published.....6
 ADRP Shares World Blood
 Donor Day Resources ..6
 Registration Opens for MD
 Workshop and Summer
 Summit6
 GLOBAL NEWS7
 COMPANY NEWS7
 CALENDAR.....8
 EQUIPMENT AVAILABLE:
9
 POSITIONS.....9

ADRP Publishes Collections and Recruitment Report

ADRP, an International division of America's Blood Centers (ABC), has published its inaugural Collections and Recruitment Report. This resource is currently available to all subscribers and the data contained within the report is representative of 40 percent of the total U.S. blood collections from calendar year 2021. Results from the report were presented at the 2022 ADRP Annual Conference and report topics include:

- Mobile collections by account type (sponsors);
- Mobile collections by account type (drive count);
- Annual drive frequency;
- Average drive size;
- Average collections per staff member;
- Average drives per recruiter (annual and monthly);
- Whole blood QNS rate;
- Automation rate; and
- Automation QNS rate.

Subscribers are encouraged to use this report as a benchmarking resource. Subscribers may request a copy [here](#).

(Source: ADRP Collections and Recruitment Report, 6/7/22) ♦

WHO Announces Webinar as Part of World Blood Donor Day Celebration

[Registration](#) is open for a World Health Organization (WHO) sponsored [webinar](#) titled, "Building effective national blood donor program[s] to ensure safe and secure blood supplies." The webinar will take place on June 15th as part of the organization's activities recognizing World Blood Donor Day (June 14th). According to a WHO announcement, attendees will hear blood bank professionals "share experiences, best practice and innovative approaches on blood donor recruitment and management."

(continued on page 2)



WHO World Blood Donor Day Webinar (continued from page 1)

Topics that will be addressed during the webinar include:

- “country experiences on developing national blood donor program[s];
- achieving 100 percent voluntary non-remunerated blood donation;
- blood donor recruitment during the COVID-19 pandemic;
- use of social media;
- the role of blood donor organizations; and
- development of donor engagement staff.”

The webinar will conclude with a “moderated panel discussion [on] how to develop an effective blood donor program[m] to ensure safe and secure blood supplies during peace time and emergencies.”

(Source: WHO [Announcement](#), 6/9/22) 💧

RESEARCH IN BRIEF

Seasonal Variation of Ferritin Among Donors. A study in *Laboratory Medicine* focused on ferritin which “is considered a good marker of iron stores in blood donors, and many blood banks use ferritin to monitor their blood donors.” The authors noted that “[f]erritin is a sensitive marker of iron deficiency, which starts to decline long before changes in hemoglobin, erythrocyte size, or serum iron concentration may be observed.” While reported in other populations “with respect to a possible seasonal variation of ferritin, however, there are, to [the authors’] knowledge, no large, published studies on blood donors.” The researchers of this study “aimed to investigate whether there is a seasonal variation for ferritin in blood donors...The study was based on the routine plasma ferritin requests for blood donors in [one] county [in] Sweden...Test results together with age and sex were retrieved from November 2009 to November 2016...The study period was selected to cover several years to minimize the potential effects of a reagent batch having a different calibration.” The study examined “[i]n total, 99,994 ferritin results...Of these, 46,426 were from male and 53,568 were from female blood donors...The median ages of females and males were 41 years (range, 26–52) and 45 years (30–56), respectively. The median ferritin value was 34 µg/L (22–50) for the female blood donors and 51 µg/L (35–83) for the male blood donors.” The authors explained that “[t]here were significant seasonal variations for both male ($P < .0001$) and female ($P < .0001$) blood donors...The patterns were similar for males and females with the highest median values in August to October and the lowest values in April to May and December...The differences between the highest and lowest median values were 6 µg/L for male and 5 µg/L for female blood donors...This corresponds to approximately 12 percent difference for males and 15 percent difference for females.” The study concluded that “[f]erritin

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.

RESEARCH IN BRIEF (continued from page 2)

shows a clear seasonal variation in this cohort of blood donors.” The authors also added that “[f]urther studies are warranted to evaluate whether these changes also influence the number of deferrals for iron deficiency.”

Citation: Saldeen, J., Carlsson, L., Larsson, A. [Seasonal Variation of Ferritin among Swedish Blood Donors](#). *Laboratory Medicine*. 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

BRIEFLY NOTED

The Biomedical Excellence for Safer Transfusion (BEST) Collaborative has extended the deadline for the call for applicants for its “Scientific Membership Application “to June 20th. The international research organization, whose objective is to improve the safety of transfusion and cell therapy and related services through standardization of analytic techniques, development of new procedures, and execution of clinical trials in hemotherapy and cell therapy, is now looking for new talent to provide continued scientific vigor and fresh ideas. Members are expected to actively participate in BEST studies, contribute ideas for new ones, and participate in BEST meetings. Projects and studies are managed by individual members through one of four teams:

- Cellular Therapy - Current Team Leads: Dave McKenna, MD; David Stroncek, MD;
- Clinical Transfusion Safety - Current Team Leads: Mark Fung, MD, PhD; Meghan Delaney, DO;
- Conventional Components - Current Team Leads: Dana Devine, PhD; Rebecca Cardigan, PhD; and
- Donor Studies - Current Team Leads: Marc Germain, MD; Ralph Vassallo, MD.

Applications with a letter of interest and CV may be submitted via the BEST [website](#). Applications will be accepted through June 20th. Decisions will be announced by September 2022, with the first meeting of the refreshed membership to be held Spring 2023.

(Source: BEST Collaborative [Announcement](#), 6/6/22)

The Association for the Advancement of Blood & Biotherapies’ (AABB) Transfusion Transmitted Diseases (TTD) Committee has published an [Interim Fact Sheet](#) on the monkeypox virus. This follows a previously released monkeypox virus outbreak [summary](#). Monkeypox is not known to be transfusion transmissible and there have been no documented cases of transmission via blood transfusion.

(Source: AABB Monkeypox [Interim Fact Sheet](#), 6/8/22) 💧

PEOPLE

[Amber Gilbert](#) has been named vice president of Business Intelligence for the National Blood Collaborative (NBC). In this role, her responsibilities will include strategic plan development and deployment for all sales strategies, marketing communications, and public relations functions. “I am honored to be joining NBC and appreciate the Board’s trust and support,” said Gilbert in a news release. “I’ve been privileged to work in the industry for nearly two decades and, as it evolves, I look forward to the opportunity to help community blood centers in their efforts to support patients and save lives.” The NBC news release added that, “Ms. Gilbert has more than 16 years of experience in the blood banking industry, including a diverse background in operational implementation, product procurement and distribution, and vendor relations. She began her blood banking career in 2006 at the Oklahoma Blood Institute as a laboratory technician in the

(continued on page 4)

PEOPLE (continued from page 3)

Infectious Disease Testing Laboratory and spent the next 14 years serving in several roles, including external accounts manager...In 2020, [Ms.] Gilbert joined American Red Cross Cell and Gene Therapy Solutions. Most recently, as Director of Client Relationship Management, she was responsible for supporting clients and internal operations to provide collection of cells for use in research development, clinical and commercial production.” Billy Weales, president and chief executive officer of The Blood Center (New Orleans, La.) added in the news release, “We are extremely excited to have Amber assume the leadership reigns as vice president of Business Intelligence for NBC with the utmost confidence she will take the organization and its owners to new heights.”

(Source: NBC [News Release](#), 6/6/22)




[Dana Devine, PhD](#) has been elected as President of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Her four year-term will begin on September 29th as she succeeds Ziggy Szczepiorkowski, MD, PhD. “I am very hon[o]red to lead the BEST Collaborative,” said Dr. Devine in a news release. I attended my first BEST meeting in 2002. I subsequently joined the Conventional Components team under the leadership of Dr. Sherrill Slichter and Nancy Heddle. I became team co-lead with Dr. Pieter van der Meer and continue in this role today. Having spent a number of years on the BEST executive, I have seen the organization ‘in action.’ We continue to prosper as a research collaborative, publishing excellent quality papers in good journals.” Dr. Devine is currently “the director of the University of

British Columbia Cent[er] for Blood Research and the chief scientist at Canadian Blood Services. [She also is currently serving as] the president of [the] Association for the Advancement of Blood and Biotherapies. [Dr. Devine] chairs the medical advisory committee for the American Red Cross and the medical advisory board for Macopharma...She is [also] a member of the research advisory boards of the Australian Red Cross Lifeblood, Vitalant, and the Bloodworks Northwest. [She] completed her PhD at Duke University under the direction of Dr. Wendell F. Rosse [and] holds an MSc in marine biology from the Boston University Marine Program located in Woods Hole, Massachusetts.”

(Source: BEST Collaborative [News Release](#), 6/2/22) 💧

IN MEMORIAM



Lawrence Dean Petz, MD passed away on June 2nd at the age of 90. Dr. Petz, affectionately known as “LP” or Larry by his staff, authored the definitive textbook *Immune Hemolytic Anemias* with his friend and colleague George Garratty, PhD, FRCPath and was responsible for the comprehensive medical textbook *Clinical Practice of Transfusion Medicine*. His many residents knew him as an incredibly encouraging and supportive mentor. During his tenure as Chief of the Hematology-Immunology Research Unit at Pacific Hospital in San Francisco, he and Dr. Garratty collaborated on patient cases involving immune hemolytic anemia. Their work became the subject of innumerable scientific articles and the basis of their two editions of *Immune Hemolytic Anemias*. Later in his career, Larry passionately pursued a cure for HIV using cord blood homozygous for CCR5-Delta 32 mutation. Larry helped establish the bank of these special units that helped cure a recent HIV patient. His achievements have been

(continued on page 4)

IN MEMORIAM (continued from page 3)

recognized by many international, national, and state organizations through awards and honors. These include:

- the Association for the Advancement of Blood and Biotherapies (AABB) Emily Cooley Memorial Award and Lectureship (1991);
- CBBS Owen F. Thomas Award (1997);
- AABB Tibor Greenwalt Memorial Award and Lectureship (2006);
- AABB George Fantas Medal for Lifetime Achievement (2010);
- the CBBS Herbert Perkins Scientific Lecture (2015); and
- the AABB Presidential Award (2017).

His first wife, Thelma predeceased him, and they had no children. He is survived by his current wife Elizabeth, who shared his love of music and travel, his stepdaughter Charmante and grandchildren Hollie, Bryson, and Alexander, his sister-in-law, Bobbie Petz, and niece, Jeri Petz. No commemoration or service will be held at Larry's request.

Contributed by Eileen Selogie, MT(ASCP)SBB, Executive Director of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative ♦

MEMBER NEWS

South Texas Blood & Tissue (San Antonio, Texas) recently [announced](#) that it will participate in the National Institutes of Health's (NIH) "All of Us" Research Program through the blood bank's Center for Advanced Therapies. According to the announcement, South Texas Blood & Tissue is part of the effort to add "at least 1 million people to the All of Us study, which will collect long-term data" and use it to help target healthcare and medical research advancements. "The All of Us program is designed to look at the influences of environment, lifestyle, genetics, and family health history on health status going forward over time," said South Texas Blood & Tissue's Vivienne Marshall, PhD in the announcement. "We're part of a prestigious group of organizations across the country working on this study...It's important for us to represent our diversity in this part of the country. We don't want new drugs or medical treatments to be developed that only cater to the majority. We would like to see our minority population fully involved in the process."

(Source: South Texas Blood & Tissue [Announcement](#), 5/10/22) ♦

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

We Welcome Your Letters

The ABC Newsletter welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the ABC Newsletter. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

June Blood Bulletin Published

America's Blood Center's (ABC) has published the June 2022 edition of the [Blood Bulletin](#), titled "Obstetric Hemorrhage — Are You Prepared?" The article was written by Nanci Fredrich, RN, BSN, MM, Transfusion Safety & Blood Management Officer at Versiti, Richard Gammon, MD, Medical Director at OneBlood, Nancy Van Buren, MD and Jed Gorlin, MD, MBA, Medical Directors at Innovative Blood Resources and Community Blood Center of Kansas City, divisions of New York Blood Center, and Theresa Nester, MD, Co-Chief Medical Officer at Bloodworks Northwest. Contributors included Kerry O'Brien, MD, Medical Director of the Blood Bank at Beth Israel Deaconess Medical Center, and Rita Reik, MD, FCAP, Chief Medical Officer at America's Blood Centers. [Blood Bulletin](#) is reviewed and edited by ABC's Scientific, Medical, and Technical (SMT) Publications Committee. ABC publishes the Blood Bulletin for use by member blood centers in their educational programs as a value-added service for hospital customers.

(Source: MCN 22-050, 6/2/22)

ADRP Shares World Blood Donor Day Resources

With World Blood Donor Day (WBDD) (June 14th) less than a week away, ADRP, an International division of America's Blood Centers (ABC), has created a centralized [hub](#) of WBDD resources to assist blood centers in celebrating and thanking blood donors for their lifesaving work. Assets include logos in multiple languages from the World Health Organization (WHO) which selected Mexico as this year's host nation.

Registration Opens for MD Workshop and Summer Summit

America's Blood Centers (ABC) launched [registration](#) for the [ABC Medical Directors Workshop and ABC Summer Summit](#) taking place August 2-4 in Minneapolis, Minn. A [preliminary program](#) is now available. Over the course of two days, attendees will hear case study rounds, engaging discussions, and have many networking opportunities to connect with peers and colleagues. [Hotel reservations](#) can be made now through the ABC block. ♦

Upcoming ABC Webinars – Don't Miss Out!

- **The Clinical Laboratory Workforce: Understanding the Challenges to Meeting Current and Future Need-ASCP Blueprint Webinar** – July 20th from 3-4 PM EDT. More information coming soon.
- **ABC SMT Journal Club Webinar** – August 10th from 3-4 PM EDT. More information coming soon.
- **ABC HIPAA & Privacy in Blood Banking Webinar** – September 13 from 3-4 PM EDT. More information coming soon.
- **ABC Cybersecurity Threats & Mitigation for Blood Centers Webinar** – September 20 from 3-4 PM EDT. More information coming soon.

GLOBAL NEWS

The World Health Organization (WHO) [published](#) updated interim recommendations for the use of the Janssen (Johnson & Johnson) COVID-19 vaccine. The recommendations contain results of additional data from ongoing clinical trials of the vaccine. The WHO previously granted the Janssen COVID-19 with the Emergency Use Listing (EUL) and states that the “vaccine is safe and effective for all individuals aged 18 and above” and that “[a] single dose regimen, in keeping with the EUL recommendations for this vaccine, remains an acceptable option for countries, especially when faced with supply constraints and difficulties to reach remote populations. However, given the evidence demonstrating improved protection with a second dose, WHO recommends that all efforts should be taken to provide two doses, in particularly to the highest and high priority-use. The administration of the second dose will result in increased protection against symptomatic infection, and against severe disease.” Last month, the U.S. Food and Drug Administration [announced](#) that it had “limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.” The limitations stemmed from an updated analysis of “the risk of thrombocytopenia syndrome (TTS) following administration of this vaccine and limits the use of the vaccine to certain individuals.”

(Source: WHO [Announcement](#), 6/6/22) ♦

COMPANY NEWS

Grifols announced that its Procleix Plasmodium Assay [received](#) a CE mark from the European Union’s (EU) European Commission (EC). According to a company news release, the certification is “the first for an automated nucleic acid test[ing] (NAT) system specifically validated for screening blood donors for malaria.” Specifically, the assay “aims to improve blood safety by detecting *Plasmodium*, a mosquito-borne parasite that causes malaria and is responsible for more than 240 million infections and 620,000 deaths annually. [It] uses a whole blood sample and detects ribosomal RNA (rRNA), which is present in thousands of copies per parasite, allowing equivalent sensitivity in both individual and pooled samples.” The CE marking signifies that the assay has been assessed to meet the safety, health, and environmental protection requirements for sale in the European Economic Area (EEA). Grifols stated in the news release that the assay “will be available in all markets accepting the CE mark certification after completion of any additional registration and notification requirements.”

(Source: Grifols [News Release](#), 6/8/22)

The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) [recommended](#) granting emergency use authorization (EUA) to **Novavax, Inc.** for the company’s COVID-19 vaccine candidate. The recommendation was based on data [published](#) in the *New England Journal of Medicine* from a phase III clinical trial of close to 30,000 individuals aged 18 or older in the U.S. and Mexico. The results reported from the trial showed that the vaccine demonstrated 90.4 percent efficacy (95 percent confidence interval [CI], 82.9 to 94.6; $P < 0.001$) with a reassuring safety profile. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups. The most common adverse reactions observed during the trial (frequency category of very common $\geq 1/10$) were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. The data showed that overall, the rate of myocarditis was balanced between the vaccine and placebo arms (0.007 percent and 0.005 percent) and in the post-crossover portions of Novavax trials the observed cases

(continued on page 8)

COMPANY NEWS (continued from page 7)

were all within the expected rate...[The vaccine] is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19.”

(Source: Novavax, Inc. [News Release](#), 6/7/22)

Moderna, Inc. [announced](#) findings from a preliminary data analysis of a clinical trial of an additional or “booster” dose of its modified COVID-19 vaccine specifically designed to the Omicron variant. According to the news release, the booster “met all primary endpoints in the Phase II/III trial including neutralizing antibody response against Omicron when compared to a 50 µg booster dose [of the company original COVID-19 vaccine] in baseline seronegative participants. Pre-specified criteria for superiority as measured by neutralizing geometric mean titer ratio (GMR) with the lower bound of the confidence interval >1 was met. The GMR and corresponding 97.5 percent confidence interval was 1.75 (1.49, 2.04). A booster dose of the modified COVID-19 vaccine increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. Primary endpoints of non-inferiority against ancestral SARS-CoV-2 were also met, with GMR against ancestral SAR-COV-2 (D614G) of 1.22 (1.08-1.37).” The modified vaccine is a “bivalent targeting two viral strains simultaneously.”

(Source: Moderna, Inc. [News Release](#), 6/8/22) ◆

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2022

June. 29-30. **FDA CTGTAC Meeting (Virtual)**. More information available [here](#).

Aug. 2-4. **ABC Summer Summit and Medical Directors Workshop, Minneapolis, Minn.** Registration is [open](#). More information available [here](#).

Aug. 29-30. **National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and the Office of the of the Assistant Secretary of Health (OASH) of the Department of Health and Human Services (HHS) 2022 State of the Science in Transfusion Medicine Workshop (Virtual)**. More information coming soon.

Sept. 19-22. **American Association of Tissue Banks Annual Meeting, San Antonio, Texas**. More information available [here](#).

Sept. 21-22. **28th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Porto, Portugal**. Registration is [open](#). More information available [here](#).

Sept. 28-29. **2022 ADRP Master Class (Virtual)**. More information coming soon.

Sept. 28-29. **BEST Meeting LXIV, Cocoa Beach, Fla.** More information available [here](#).

Oct. 1-4. **Association for the Advancement of Blood & Biotherapies Annual Meeting, Orlando, Fla.** Registration is [open](#). More information available [here](#).

2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** More information coming soon.

May 9-11. **2023 ADRP Conference**. More information coming soon. ◆

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

EQUIPMENT AVAILABLE:

For Sale. New and Unused CompoMat G5 Units. The Blood Bank of Alaska has three new and unused CompoMat G5 Units for sale. These units have not been validated or used. If interested, please contact Bryan Baynard at bbaynard@bbak.org or (907) 222-5664.

POSITIONS

Chief Administrative Officer (Shreveport, LA). LifeShare Blood Center is seeking an experienced human resources, risk management, or business administration professional as our Chief Administrative Officer (CAO). Reporting to the President & CEO, the CAO develops and administers Company-wide policies and practices to facilitate business operations and manage risk exposures; ensures compliance with applicable laws, standards and regulations governing various areas of responsibility; and provides executive leadership of human resources, safety, quality assurance, and information systems and technology functions. Please join us in our important mission to connect blood donors and the lives they impact! LifeShare offers a competitive beginning salary, commensurate with experience and a generous benefits package, including employer-paid medical, life and disability insurance; employer base retirement and matching contributions (6%) to the 401(k) savings plan, paid time off bank, and employee wellness program. Visit our [Careers Page](#) to apply.

Regional Operations Director (Baton Rouge, LA). LifeShare Blood Center is seeking an Operations Director to oversee blood collection and donor recruitment operations in the Baton Rouge, LA region. Relocation assistance may be available for the right candidate. The Operations Director will develop and implement strategic and tactical plans for donor recruitment and collections within the donor center and community-based activities; direct, develop and coach teams for achievement of established goals and KPI's; develop relationships with community leaders and groups to promote our mission and business needs; ensure operations adhere to standards and regulations governing the blood banking industry; and model LifeShare's mission and values, integrating them into daily decisions, behaviors and actions. **Join us in our important mission to connect blood donors and the lives they impact!** LifeShare offers a competitive salary, commensurate with experience plus incentive bonus opportunities, as well as a generous benefits package, including employer-paid medical, life and disability insurance; 401k with employer contributions (6%), paid time off bank, and employee wellness program. Visit our [Careers Page](#) to apply.

Clinical Laboratory Scientist Specialist. Ranked No. 5 in the nation by U.S. News & World Report, Children's Hospital Los Angeles (CHLA) provides the best care in California. Here world-class experts in medicine, education, and research work together to deliver family-centered care half a million times each year. Position Summary: The CLS Specialist functions as a licensed staff member performing duties approved by California Business and Professions Code, CLIA, and other regulatory agencies. Plan, coordinate, and lead all areas of Transfusion Medicine (TM) in activities related to quality and regulatory affairs. Review of all SOPs. Review of all validation plans. Review of all quality audits and other required assessments. Management of the overall deviation management program. Oversee the implementation and the interpretation of the effects of all new and revised standards and guidelines from regulatory and accrediting agencies on TM operations. Serve as the primary contact and liaison with all external regulatory and accrediting agencies. Maintain all licenses, registrations, and certifications required for TM. Education/Licensure: Bachelor's degree in Biology or related science required. Valid California CLS license required. SBB preferred. **Minimum Qualifications:** Five plus years of relevant experience. Prior experience performing quality functions and working with regulatory and accrediting agencies preferred. AABB assessor preferred. Please click [here](#) to view the full job description and apply.

Director of Quality. National Blood Testing Cooperative is now interviewing for a Director of Quality who through direct or delegated oversight, ensures financial feasibility, customer, and employee desirability of business decisions, strategic planning, development and execution of all quality systems for the Donor Testing Lab. Creates and fosters a collaborative environment in the organization that allows all employees to work together to further the mission and vision of the organization to ensure that the organization is increasing customer value, growing in a smart and efficient manner,

(continued on page 10)

POSITIONS (continued from page 9)

driving operational efficiency, inspiring the talent base, and continually reinventing the business. A BA in Life Science, nursing, or allied science discipline. Medical Technology (MT), Medical Laboratory Specialist (MLS), or at a minimum, Medical Lab Technology (MLT) certification preferred. Valid driver's license required. A minimum of two to four years Management/Supervisory experience with emphasis on employee development, performance evaluations, coaching and counseling and daily work management. Experience/involvement in strategic planning and execution. Minimum four to six years of Quality Assurance/Quality Management experience with emphasis on quality assurance, process design, error management, document control, auditing, licensure, and ensuring compliance. If you meet the above qualifications, please apply by sending your resume to: wendy@nationalbloodcollaborative.org. **EOE/AAE**

QRA Supervisor. Responsibilities: Quality Assurance/Training/ GMP/GTP/GLP: Lead the department's quality activities, initiatives, and process improvement activities. Perform training on QRA core functions and activities, Good Manufacturing Practice/Good Tissue Practice/Good Laboratory Practice, and safety. Compliance: Ensure compliance to current regulations and accreditation requirements by federal, state, county, and accreditation agencies. Team Leadership: Manage the performance of direct reports. Set team objectives, priorities, and resources to align staff with Blood Center objectives. Safety: Lead the safety, emergency, and disaster management of the organization. Quality Management System: Provide oversight on the appropriate use of the quality management tools in handling the various documents, records, and activities of the blood center. Registration and Licensure: Ensure all licenses, permits and certificates are current and regulatory requirements are met. Qualifications: Bachelor's degree required. One to two plus years supervisory experience in a regulated or GMP (Good Manufacturing Practice) required. Please click [here](#) to view the full job description and apply.

Medical Technologist – Overnight/Shift Differential. LifeSouth Community Blood Centers is currently seeking a skilled individual for a **Medical Technologist** position in our Immunohematology Reference Laboratory (IRL) in **Jacksonville, FL**. This position is responsible for performing and interpreting clinical laboratory tests that require the exercise of independent judgment. **We are looking to fill an overnight/third shift.** Starting salary range is \$27.00 - \$32.40 an hour. Shift differential of 15 percent – 20 percent may apply for working overnight hours. Applicants should apply [here](#).

President/CEO. Shepard Community Blood Center is seeking a President/CEO to succeed a very effective CEO who is retiring December 31, 2022. Shepard, located in

Augusta, GA, is a successful (and financially sound), not-for-profit, independent organization proudly serving 29 hospitals and helicopter ambulatory services spanning 40 counties in Georgia and South Carolina. The preferred candidate is one who has demonstrated leadership experience in the blood/blood product collection industry, although persons with related health care industry experience may be considered. The successful candidate must possess exceptional strategic planning abilities and have strong interpersonal skills to maintain and develop mission-supporting relationships in the health care and local communities we serve. This executive leadership position is accountable for operational objectives and providing leadership and direction to the organization and working closely with the Board of Directors to strategically plan and ensure strategic plan is implemented to conform to Shepard's mission, vision, and core values. That includes the demonstrated ability to build cohesive teams to drive operational success in a challenging, forward moving blood industry with highly regulated environments. Candidates must be able to formulate a clear vision of how best to respond to ever-changing challenges in the industry. Candidates must have at least ten years of progressive managerial experience and hold a baccalaureate degree and either an MHA or MBA (or equivalent) from an accredited college or university. EOE/M/F/Vet/Disabled compliant. Please submit a resume with salary history and a cover letter explaining why you meet the requirements of this position to Jerry@GeraldWoods.net or mail to Shepard Community Blood Center, Attn: Jerry Woods, 1533 Wrightsboro Road, Augusta, GA, 30904. The deadline for applications is **June 15, 2022**.

Director of Finance. LifeSouth Community Blood Centers is currently seeking an individual to join our team as the Director of Finance in Gainesville, FL. This position is charged with ensuring the stability of LifeSouth's finances through planning, directing, and controlling financial functions, including establishing appropriate control environments, financial reports for management on the company's financial status, preparing financial reports and analysis, and overseeing the development and implementation of effective financial and accounting systems. The selected candidate will also manage the Purchasing and Accounting departments. Applicants should apply [here](#).

QA Specialist (R2216359) (Stanford Blood Center). Responsibilities: Cover the quality essentials and perform regulated tasks addressing organization, resources, equipment, supplier & customer issues, process control, document and records, deviations and adverse events, assessments, process improvement, and facility & safety. Assist in training appropriate personnel pertaining to QRA and safety activities. Ensure compliance to current regulations, accreditation standards, guidance documents

(continued on page 11)

POSITIONS (continued from page 10)

and policies and procedures consistent with the latest releases of Code of Federal Regulations, California Code of Regulations, Health & Safety Codes, Business and Professions Code, AABB Blood Bank and Transfusion Services and College of American Pathologist accreditation standards including local Bills (Assembly and Senate Bills) and applicable County Directives. Perform regulated document reviews of standard operating procedures, forms, training plans, other pertinent documents, change controls, and validations. Also, review and monitor incident and deviation management through the different Quality Management System applications. Act as member of the safety committee member and perform designated roles as Emergency Response Team (ERT), Assembly Point Coordinator (APC). Facilitate external inspection conducted by inspectors. Qualifications: Bachelor's degree required. Three plus years to five years in blood banking, laboratory, or manufacturing with solid familiarity of GMP, safety in a manufacturing setup, and CAL-OSHA regulations required. Please click [here](#) to view the full job description and apply. ♦